ARIAN protocol: a phase III study of sacituzumab and zimberelimab for the treatment of patients with non-small cell lung cancer

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Provencio M.
  • Aguiar D.
  • Antoñanzas M.
  • Areses M.C.
  • Azkárate A.
  • Barba A.
  • Bernabé R.
  • Blanco R.
  • Borregón M.
  • Campos B.
  • Coves J.
  • de Castro J.
  • Domènech M.
  • Dómine M.
  • García Campelo R.
  • Lucía-Gozálvez C.
  • Lázaro-Quintela M.
  • Insa A.
  • López Castro R.
  • Martínez-Marti A.
  • Medina S.
  • Moreno M.Á.
  • Nadal E.
  • Olivares-Hernández A.
  • Reguart N.
  • Sala M.Á.
  • Medina K.
  • Vila L.
  • Massutí B.

Grupos

Abstract

Lung cancer remains the leading cause of cancer-related deaths worldwide. Despite advances to improve treatment in resectable early-stage and locally advanced non-small cell lung cancer (NSCLC), survival rates after 5 years remain low, with a high risk of disease progression. Patients who fail to achieve a pathological complete response (pCR) after neoadjuvant treatment have unfavorable outcomes. ARIAN is a phase III, multicenter, open-label, randomized trial evaluating adjuvant treatment in adults with stage IB-IIIB (N2) NSCLC who have undergone neoadjuvant chemo-immunotherapy but did not achieve pCR after completing surgical resection. Patients will be stratified based on programmed death receptor-ligand 1 (PD-L1) tumor expression and randomized (1:1:1) to observation for 10 months (Arm 1), zimberelimab for 13 cycles (Arm 2), or sacituzumab govitecan and zimberelimab for 8 cycles followed by zimberelimab monotherapy for 5 cycles (Arm 3). The primary endpoint is disease-free survival, and secondary endpoints include overall survival and safety. © 2026 Informa UK Limited, trading as Taylor & Francis Group.

Datos de la publicación

ISSN/ISSNe:
1471-2598, 1744-7682

EXPERT OPINION ON BIOLOGICAL THERAPY  TAYLOR & FRANCIS LTD

Tipo:
Article
Páginas:
441-449
PubMed:
42159280
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
1,001 SCImago ℠
Cuartil:
Q1 SCImago ℠

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Antibodies, Monoclonal, Humanized; Camptothecin; Carcinoma, Non-Small-Cell Lung; Humans; Immunoconjugates; Lung Neoplasms; sacituzumab govitecan; zimberelimab; antibody conjugate; camptothecin; monoclonal antibody; sacituzumab govitecan; adjuvant therapy; adult; alopecia; anemia; Article; cancer immunotherapy; chemoimmunotherapy; computer assisted tomography; conservative treatment; constipation; controlled study; disease free survival; drug withdrawal; ECOG Performance Status; event free survival; fatigue; female; good clinical practice; human; hyperthyroidism; hypothyroidism; immune response; laboratory test; major clinical study; male; nausea; neoadjuvant therapy; neutropenia; non small cell lung cancer; overall survival; pathological complete response; phase 3 clinical trial; physical examination; postoperative period; vomiting; clinical trial; drug therapy; lung tumor; non small cell lung cancer; pathology

Cita

Compartir